What did we learn about hypoglycemic risk from the LEADER trial as it relates to the GLP-1 RA evaluated?

What did we learn about hypoglycemic risk from the LEADER trial as it relates to the GLP-1 RA evaluated?

What did we learn about hypoglycemic risk from the LEADER trial as it relates to the GLP-1 RA evaluated?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

John Petrie, MD, PhD

John Petrie, MD, PhD

Professor of Diabetic Medicine
University of Glasgow
Honorary Consultant Physician and Diabetologist
Glasgow Royal Infirmary and Stobhill Hospital
Glasgow, Scotland